An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Shockwave Medical, Inc. (Nasdaq: SWAV) expects to issue quarterly earnings releases and hold conference calls on the following dates: Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET), First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET), Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET), Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET). Investors can listen to the earnings conference call by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Webcasts of all earnings events will be available at https://ir.shockwavemedical.com.
Positive
None.
Negative
None.
SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:
Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET) First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET) Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET) Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET)
Investors interested in listening to the fourth quarter 2023 earnings conference call at 4:30 p.m. eastern time on Thursday, February 15, 2024, may do so by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096. Live and archived webcasts of all earnings events will also be made available at https://ir.shockwavemedical.com.
Dial-in information for future earnings calls will be provided at later dates.
About Shockwave Medical, Inc. Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in Europe. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.
When is Shockwave Medical, Inc. (Nasdaq: SWAV) issuing its Fourth Quarter 2023 Earnings release?
Shockwave Medical, Inc. (Nasdaq: SWAV) is issuing its Fourth Quarter 2023 Earnings release on Thursday, February 15, 2024 at 4:30 p.m. (ET).
How can investors listen to the earnings conference call for Fourth Quarter 2023?
Investors can listen to the earnings conference call by dialing (877) 704-4453 for domestic callers or (201) 389-0920 for international callers, using conference ID: 13742096.
Where can investors find the webcasts of all earnings events?
Webcasts of all earnings events will be available at https://ir.shockwavemedical.com.
shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen